본문 바로가기
KERD
논문KCI 등재

거대세포 바이러스 특이항원 자극 인터페론-감마효소결합면역흡착점적법/ 효소결합면역흡착측정법의안전성과 유효성에 대한 체계적 문헌 고찰

Safety and Effectiveness of Cytomegalovirus Specific Antigen Induced Interferon-Gamma ELISPOT/ELISA: A Systematic Review

한주희|최원정|이월숙|신채민
대한임상미생물학회 (Korean Society of Clinical Microbiology)|2021.06|Annals of Clinical Microbiology|제24권 제2호|pp. 31-43|DOI 10.5145/ACM.2021.24.2.2

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

EffectivenessSafetyCMV-Specific Antigen-Induced Interferon GammaEnzyme-linked immunosorbent assayEnzyme-linked immunospot assay

초록

배경: 거대세포바이러스 특이항원 자극 인터페론-감마 효소결합면역흡착점적법/ 효소결합면역흡착측정법은면역저하환자에서 CMV 감염/질환의위험예측검사로서안전성및유효성을체계적문헌고찰방법을통하여확인하고자하였다. 방법: 문헌 검색은 MEDLINE, EMBASE 및 Cochrane library를 포함한 전자 데이터베이스를 통해수행되었으며, 884편이검색되었다. 최종적으로선택된문헌은 25편(코호트연구 15편, 단면연구10편)으로 연구대상이 고형장기 이식환자, 조혈모세포 이식환자, 혈액투석 환자이었다. 두 명의연구자는독립적으로자료추출및문헌의질평가를수행하였다. 결과: 선택된 대부분의 연구는 고형장기 이식환자를 대상으로 한 연구였다. 동 검사는 체외에서이루어지는 검사로 안전하다. 유효성은 대부분이 예후 관련 결과 발생의 위험도는 검사결과 활성군 대비 비활성군에서 CMV 사건발생(CMV 감염, CMV 질환 등) 위험비 또는 오즈비가 유의하게 높았고, 카플란-마이어 생존분석 결과에서도 CMV 사건 발생률이 유의하게 높았다. 그러나,CMV 세포면역반응에대한임계치가다양하였고, 예측정확도의범위가넓게보고되었다. 결론: 거대세포바이러스 특이항원 자극 인터페론 감마 효소결합면역흡착점적법/ 효소결합면역흡착측정법은고형장기이식환자에서는 CMV 감염/질환의위험을층화하여예방적/선제적치료의 방침을 결정할 수 있는 잠재성이 있는 검사이나, 임계치 확립과 검사의 표준화를 위하여 추가적인문헌적근거가필요하다.

Abstract

Background: This study evaluated the safety and effectiveness of the cytomegalovirus(CMV) Specific Antigen Induced Interferon-Gamma ELISPOT (enzyme-linked immunosorbentspot)/ELISA (enzyme-linked immunosorbent assay) procedure in predicting the risk of CMVinfection/disease in immunocompromised patients through a systematic literature review. Methods: The searched electronic databases included MEDLINE, EMBASE and the CochraneLibrary. A total of 884 non-duplicate citations were retrieved and a total of 25 studies (15cohort studies, 10 cross-sectional studies) were included in this review. Study subjects wereselected among patients with solid organ, hematopoietic stem cell transplantation, or thosewho were on hemodialysis. Data extraction and literature quality assessment were carried outindependently by two researchers. Results: Most of the studies were conducted on patients with solid organ transplants. As it isconducted outside the body, CMV Specific Antigen Induced Interferon-Gamma ELISPOT/ELISAassay was safe. Regarding its effectiveness, most studies on risk analysis based on prognosis related outcomes reported that the inactive group showed a significantly higher hazard ratioor odds ratio than the active group. Results of Kaplan-Meier survival analysis also showedthat the inactive group had a significantly higher incidence of CMV event (CMV infection,CMV disease, other events) than the active group. However, various thresholds for CMV cellimmune response were reported, as was a broad range of predictive diagnostic accuracies. Conclusion: CMV Specific Antigen Induced Interferon-Gamma ELISPOT/ELISA assay haspotential to stratify the risk of CMV infection/disease among solid organ transplant patients andto determine a policy for a prophylaxis/preemptive. However, additional literature evidence isneeded to establish thresholds for CMV cell immune response and standardized tests.

참고문헌 (35)

  1. Deborska-Materkowska D, "Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients", BMC Infect Dis, 18, pp.179~ (2018)
  2. Yang CW, "Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay", Am J Nephrol, 18, pp.373~378 (1998)
  3. Ki HK, "Cytomegalovirus infections after renal transplantation", Korean J Infect Dis, 31, pp.341~345 (1999)
  4. 기현균, "간이식 환자에서 CMV 항원혈증 검사의 임상적 유용성에 대한 고찰", Infection and Chemotherapy, 37(4), pp.199~207 (2005), 대한감염학회
  5. Jameson JL, "Harrison's principles of internal medicine" (2017), McGraw-Hill
  6. Rittà M, "Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients", New Microbiol, 38, pp.329~335 (2015)
  7. 김성한, "Diagnostic Usefulness of Cytomegalovirus (CMV)- Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of- Concept Study", Infection and Chemotherapy, 47(2), pp.105~110 (2015), 대한감염학회[DOI]
  8. Abate D, "Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients", Transplantation, 93, pp.536~542 (2012)
  9. Kotton CN, "Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation", Transplantation, 96, pp.333~360 (2013)
  10. Healthcare improvement scotland, "SIGN 50 : a guideline developer's handbook" (2014), Scottish intercollegiate guidelines network (SIGN)
  11. Bestard O, "Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation", Am J Transplant, 13, pp.1793~1805 (2013)
  12. Banas B, "Validation of T-Track CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients", BMC Immunol, 18, pp.15~ (2017)
  13. Costa C, "Evaluation of CMVspecific cellular immune response by EliSPOT assay in kidney transplant patients", J Clin Virol, 61, pp.523~528 (2014)
  14. Jarque M, "CMV-specific cell-mediated immunity at 3-month prophylaxis withdrawal discriminates D+", R+ kidney transplants at risk of late-onset CMV infection regardless the type of induction therapy, 2018, pp.102, e472~80
  15. Kumar D, "A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients", Am J Transplant, 19, pp.2505~2516 (2019)
  16. 권지수, "Comparison of the Commercial QuantiFERON-CMV and Overlapping Peptide-based ELISPOT Assays for Predicting CMV Infection in Kidney Transplant Recipients", Immune Network, 17(5), pp.317~325 (2017), 대한면역학회[DOI]
  17. Lee H, "Cytomegalovirus(CMV)immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients", PLoS One, 12, pp.e0189488~ (2017)
  18. Leone F, "Early cytomegalovirusspecific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation", Transpl Infect Dis, 18, pp.191~201 (2016)
  19. Lúcia M, "Preformed frequencies of cytomegalovirus(CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients", Clin Infect Dis, 59, pp.1537~1545 (2014)
  20. Mattes FM, "Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation", Am J Transplant, 8, pp.990~999 (2008)
  21. Nesher L, "Utility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients", J Infect Dis, 213, pp.1701~1707 (2016)
  22. Schachtner T, "CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor", Transplantation, 101, pp.e315~25 (2017)
  23. Shin KH, "CMV specific T cell immunity predicts early viremia after liver transplantation", Transpl Immunol, 51, pp.62~65 (2018)
  24. Yong MK, "Identifying cytomegalovirus complications using the Quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation", J Infect Dis, 215, pp.1684~1694 (2017)
  25. Cantisan S, "Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation", Am J Transplant, 13, pp.738~745 (2013)
  26. Fernández-Ruiz M, "Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin", Am J Transplant, 20, pp.2070~2080 (2020)
  27. Gabanti E, "Comparison of the T-cell response to human cytomegalovirus(HCMV)as detected by cytokine flow cytometry and QuantiFERON-CMV assay in HCMV-seropositive kidney transplant recipients", New Microbiol, 41, pp.195~202 (2018)
  28. Manuel O, "Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients : a multicenter cohort study", Clin Infect Dis, 56, pp.817~824 (2013)
  29. Paouri B, "Quantiferon-Cytomegalovirus assay : a potentially useful tool in the evaluation of CMV-specific CD8+T-cell reconstitution in pediatric hematopoietic stem cell transplant patients", Pediatr Transplant, 22, pp.e13220~ (2018)
  30. Sood S, "Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantation", Liver Transpl, 21, pp.1478~1485 (2015)
  31. Sood S, "Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation", Transpl Infect Dis, 20, pp.e12934~ (2018)
  32. Thompson G, "Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia", Pathology, 50, pp.554~561 (2018)
  33. Kotton CN, "The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation", Transplantation, 102, pp.900~931 (2018)
  34. Razonable RR, "Cytomegalovirus in solid organ transplant recipients-guidelines of the American society of transplantation infectious diseases community of practice", Clin Transplant, 33, pp.e13512~ (2019)
  35. Ruan Y, "Diagnostic performance of cytomegalovirus(CMV)immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation : a PRISMA-compliant article", Medicine, 98, pp.e15228~ (2019)

관련 논문AI추천

Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplantDuck Jong Han, Heungsup Sung, Hyun-Jeong Lee, Joo Hee Jung, Jun Hee Woo, Sang-Ho Choi, Sang-Oh Lee, Sung-Han Kim, Sung Shin, Sun-Mi Kim, Taeeun Kim, Yang Soo Kim, Yong Pil Chong, Young-Hoon Kim대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제2호Comparison of the Commercial QuantiFERON-CMV and Overlapping Peptide-based ELISPOT Assays for Predicting CMV Infection in Kidney Transplant Recipients신성, 권지수, 김선미, 김성한, 김영훈, 김태은, 성흥섭, 신의철, 한덕종대한면역학회 · Immune Network2017 · 제17권 제5호Diagnostic Usefulness of Cytomegalovirus (CMV)- Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of- Concept Study신성, 김선미, 김성한, 김양수, 김영훈, 성흥섭, 우준희, 이상오, 이현정, 정주희, 최상호, 한덕종대한감염학회 · Infection and Chemotherapy2015 · 제47권 제2호Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies한상훈대한감염학회 · Infection and Chemotherapy2017 · 제49권 제3호Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation김남중, 김상일, 김시호, 김윤정, 김종만, 백경란, 석혜리, 위유미, Ahn Hyung Joon, Choe Pyoeng Gyun, Huh Kyungmin, Jeong Su Jin, Kang Ji-Man, Kim Jungok, Kim Myoung Soo, Lee Sang-Oh, Lee Su Jin, Moon Chisook, Park Wan Beom, Shi Hye Jin, Sung Heungsup, Yang Jaeseok대한감염학회 · Infection and Chemotherapy2024 · 제56권 제1호Clinical applications of interferon-γ releasing assays for cytomegalovirus to differentiate cytomegalovirus disease from bystander activation: a pilot proof-of-concept study신성, 김경조, 김선미, 김성한, 김양수, 김영훈, 박상형, 성흥섭, 양석균, 우준희, 이상오, 이현정, 이호수, 최상호, 한덕종대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제5호

이 간행물의 다른 논문 (3건)

카바페넴 내성 Enterobacterales에서carbapenemase의 신속 검출 및 형별 분류를 위한두 가지 상용화된 제품의 평가이승후, 성흥섭, 김미나, 정윤실, 허규화pp. 45-53Evaluation of Seroprevalence of SARS-CoV-2 IgG in Healthcare Workers in a Tertiary Hospital in Seoul윤여민, 김한아, 문희원, 남민정, 허미나pp. 55-60First Report of Roseomonas aerofrigidensis Isolated from the Peritoneal Fluid of a Gastric Cancer Patient김소민, 송준협, 이혁민, Le Phuong Nguyen, Eris Jangpp. 61-65
원문 보기